Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

One Patient's Complete Response to Investigational Cancer Therapy Sparks Hope

(BPT) - Werewolf Therapeutics' clinical trials are underway and they're already changing lives.

For one patient with metastatic cancer, a clinical trial has led to his life-changing breakthrough. This powerful moment has inspired the "Full Moon Moment" campaign by Werewolf Therapeutics (NASDAQ: HOWL), a clinical-stage biopharmaceutical company pioneering a new class of conditionally activated cytokine therapies. The campaign aims to highlight Full Moon Moments in Werewolf clinical trials.

The inspiration behind the campaign is a patient at HonorHealth Cancer Center with metastatic cutaneous squamous cell carcinoma who experienced a complete response to Werewolf's investigational therapy, WTX-124. More than a year later, that patient's response remains sustained, offering a powerful illustration of the potential for selectively activated immune therapies in the fight against cancer.

A Novel Approach to Fighting Cancer

Werewolf's investigational* INDUKINE™ molecules are designed to activate the body's own immune system to fight cancer, with a focus on minimizing side effects often associated with other treatments. The company's approach targets diverse and difficult-to-treat cancers that may be resistant to other therapies.

Two key therapies are currently in clinical trials:

  • WTX-124 is designed to harness the IL-2 cytokine to directly stimulate cancer-fighting immune cells within the tumor
  • WTX-330 is designed to employ IL-12 to activate a wide range of immune cells to trigger a broad and rapid immune response against the cancer

Are You or a Loved One a Candidate for a Clinical Trial?

For patients and caregivers exploring treatment options for advanced cancers, Werewolf's clinical trials may offer a new path forward. Specific details for each trial are listed below.

WTX-124 Clinical Trial (NCT05660384)

This trial is evaluating WTX-124 for patients with several types of advanced or metastatic solid tumors. It is currently focused on individuals with specific skin cancer and other malignancies where immunotherapy is a critical part of the treatment, including:

  • Cutaneous Malignant Melanoma
  • Cutaneous Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer

WTX-330 Clinical Trial (NCT06939283)

This study is evaluating WTX-330 in adults with certain advanced solid tumors or lymphoma. The trial is enrolling patients with specific cancers who have progressed on other standard therapies. The trial arms are focused on patients with:

  • Metastatic Cutaneous Melanoma that has shown resistance to other checkpoint inhibitor immunotherapies
  • Metastatic Colorectal Cancer (specifically microsatellite-stable or MSS) that is immunotherapy-naïve
  • Advanced Non-Hodgkin Lymphoma, including follicular lymphoma or diffuse large B-cell lymphoma, who have relapsed or have disease that is resistant to at least two prior therapies

As these therapies continue to be studied, Werewolf Therapeutics hopes to create more "Full Moon Moments" with the potential to change the lives of patients with cancer.

It is important for patients to discuss all treatment options, including the potential risks and benefits of joining a clinical study, with their healthcare professional.

To learn more about these ongoing clinical trials, please visit https://werewolftx.com/clinical-trials/ or contact clinicaltrials@werewolftx.com.

*WTX-124 and WTX-330 are Investigational therapies and have not been approved by the FDA or any other regulatory agency.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.